new JAK sales

Discussion in 'Pfizer' started by Anonymous, Apr 14, 2013 at 10:45 AM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    Is it worth trying to sell the new JAK product?

    Strong established products with Enbrel (certainly very familiar) and Humira.

    Any idea how many rep openings there are going to be?
     

  2. Anonymous

    Anonymous Guest

    WHAT PRODUCT ARE YOU TALKING ABOUT MORON?
     
  3. Anonymous

    Anonymous Guest

    Its a New JAK City, baby! This is where it's at.
     
  4. Anonymous

    Anonymous Guest

    Well...your company sells the only JAK on the market. My guess op is asking about that one.
     
  5. Anonymous

    Anonymous Guest

    Better to just JAK off.
     
  6. Anonymous

    Anonymous Guest

    you don't know JAK, you must be some kind of JAK A$* - or never leaving the house JAK'n OFF.
     
  7. Anonymous

    Anonymous Guest

    best post ever - no wonder that drug is tanking
     
  8. Anonymous

    Anonymous Guest

    This mentioned on investor conf call w ELT:

    $11 million in sales 1st qtr 2013, after stocking up wholesale. Not exactly blockbuster status.
     
  9. Anonymous

    Anonymous Guest

    Do you think they will combo this drug with me'off?
     
  10. Anonymous

    Anonymous Guest

    Pfizer should have priced it 25% less than current market, then built in double digit price increases once market share established. Typical Pfizer to go all in anal retentive
    and blow their wad up front, it's Pfgreed!
     
  11. Anonymous

    Anonymous Guest

    NOT INCLUDING PFIZER WON'T CONTRACT WITH HMO'S EITHER